Projected 2018 sales:
$1.516 billion
2012 sales: $1.520 billion

Kogenate's newest iteration was welcomed with open arms by hemophilia patients when it hit the U.S. market in October 2008. Approved to reduce the frequency of bleeding episodes and the risk of joint damage in patients up to age 16 with severe hemophilia A, Kogenate FS Antihemophilic Factor was the first of its kind and marked a milestone in patient care, especially that of young children.

At the time, Bayer was in the process of beefing up its specialty pharmaceutical business and, in particular, its hemophilia offerings, grabbing up Maxygen's hemophilia drug-development program in July of that year.

These days, Bayer HealthCare, which encompasses Kogenate and pulls in about half the revenue for its parent Bayer, is working to grow its prescription drug business, and it did so successfully last year with growth of 8%. CEO Marijn Dekkers has pledged to grow Bayer HealthCare by 6% per year over the next several years, and blockbuster Kogenate will surely be playing a part.

For more:
Bayer gets Kogenate approval


Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

Vaccine maker Inovio has accused a longtime manufacturing partner of hampering its efforts to produce 1 million doses of a potential COVID-19 vaccine.